Keynote B21
The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to overall survival (OS). The primary hypotheses are that pembrolizumab + adjuvant chemotherapy is superior to placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to DFS as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to OS.
CLINICALTRIALS.GOV IDENTIFIER:
NCT04634877
When speaking to your doctor, please have the trial identifier number available.
All patients who enroll in the trial will receive chemotherapy with or without radiotherapy while on the study.
50% will receive pembrolizumab
50% will receive placebo
Tests the medicine or vaccine in large groups of trial participants (from several hundred to several thousand). For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics, or physician offices.
Dates
Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.
Conditions
Endometrial Neoplasms
Age Range
18 - No Age Maximum
Sex
Female
Locations provided may not reflect the most current site information. Please call the number provided in the location results to confirm.
Print this page
Email this page